Dr. Benjamin A. Gartrell, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 271
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
OH license 57.010155
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Montefiore Medical Center Bronx, NY
- White Plains Hospital Center White Plains, NY
- Montefiore St Luke's Cornwall Newburgh, NY
Medical groups
- Montefiore Medical Center (2,820 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 271
- Services billed
- 840
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 259 | 113 |
| Established patient office or other outpatient visit, 20-29 minutes | 214 | 119 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 79 | 39 |
| Established patient office or other outpatient visit, 40-54 minutes | 43 | 30 |
| New patient office or other outpatient visit, 45-59 minutes | 28 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 18 |
| Telephone medical discussion with physician, 21-30 minutes | 15 | 12 |
| Hospital discharge day management, more than 30 minutes | 15 | 15 |
| Emergency department visit with moderate level of medical decision making | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Abiraterone Acetate | 660 |
| Prednisone Other prescribers in Bronx, NY | 456 |
| Orgovyx (relugolix) | 83 |
| Erleada (apalutamide) | 37 |
| Bicalutamide | 32 |
| Tamsulosin Hcl Other prescribers in Bronx, NY | 31 |
| Nubeqa (darolutamide) | 27 |
| Xtandi (enzalutamide) | 24 |
| Amlodipine Besylate Other prescribers in Bronx, NY | 21 |
| Cabometyx (cabozantinib s-malate) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $6,045 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $2,800 |
|---|---|
| Janssen Scientific Affairs, LLC | $1,836 |
| Janssen Biotech, Inc. | $1,409 |
| Consulting Fee | $5,853 |
|---|---|
| Food and Beverage | $192 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 8, 2025 | Consulting Fee PLUVICTO · Oncology | $2,800 |
| Janssen Scientific Affairs, LLC Jun 12, 2025 | Consulting Fee ERLEADA · Oncology | $1,665 |
| Janssen Biotech, Inc. Sep 19, 2025 | Consulting Fee ERLEADA · Oncology | $1,388 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 13 companies. The companies reported $668,097 in research payments for these studies, mostly to the institutions running them.
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT03972657 - A phase 3 randomized double blind placebo controlled study of PF06821497 mevrometostat with enzalutamide in metastatic castration resistant prostate cancer MEVPRO2
Pfizer Inc. - An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Ol…
Novartis Pharmaceuticals Corporation - A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With …
Amgen Inc. - A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Pros…
AstraZeneca UK Limited - An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals Corporation - A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensiti…
AstraZeneca Pharmaceuticals LP - FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company · Recruiting · NCT05614739 - A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer
Novartis Pharmaceuticals Corporation - A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterio…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.